Munch M, Riisom K, Christensen T, Møller-Larsen A, Haahr S
Department of Medical Microbiology and Immunology, University of Aarhus, Denmark.
Acta Neurol Scand. 1998 Mar;97(3):171-4. doi: 10.1111/j.1600-0404.1998.tb00632.x.
The objective of this study was to evaluate and investigate the significance of the previously found 100% seropositivity toward Epstein-Barr virus (EBV) found in multiple sclerosis (MS) patients in contrast to healthy controls. Using a commercially available ELISA-test (Biotest), which differentiates infections with EBV into previous infections, primary infections, reactivated infections and no previous infection, we found 137 of 138 MS patients and 124 of 138 healthy controls seropositive. A primary infection in 4 of the 124 EBV seropositive healthy controls in contrast to no primary infections in the MS EBV seropositive group was significant (P=0.049652, Fishers exact test). This may be suggestive of a lack of primary infections in MS patients, and thus strengthens the idea that MS patients are infected with EBV before development of MS. Further studies are in progress to analyse whether EBV infection is a prerequisite for the development of this disease.
本研究的目的是评估和调查此前在多发性硬化症（MS）患者中发现的针对爱泼斯坦-巴尔病毒（EBV）100%血清阳性的意义，并与健康对照进行对比。使用一种市售的酶联免疫吸附测定（ELISA）检测法（Biotest），该方法可将EBV感染区分为既往感染、原发性感染、再激活感染和无既往感染，我们发现138例MS患者中有137例血清呈阳性，138例健康对照中有124例血清呈阳性。124例EBV血清阳性的健康对照中有4例发生原发性感染，而MS EBV血清阳性组中无原发性感染，这一差异具有统计学意义（P=0.049652，Fisher精确检验）。这可能提示MS患者缺乏原发性感染，从而强化了MS患者在MS发病前就已感染EBV的观点。目前正在进行进一步研究，以分析EBV感染是否是该疾病发生的先决条件。
